Teva net profit and sales rise 6%

Teva also has a big pipeline, with 145 product applications awaiting final approval by the US Food and Drug Administration.

November 9, 2005 06:41
2 minute read.
teva logo 88

teva logo 88. (photo credit: )


Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analysis from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief


Teva Pharmaceutical Industries' third-quarter net profit and sales both rose 6 percent, as record sales of its flagship drug Copaxone and a low tax rate helped offset an increase in expenses. The Jerusalem-based company said Tuesday that in the three months ended September 30, net profit rose to $267.1m. from $251.5m., diluted earnings per share rose to 40 cents from 37 cents, and sales rose to $1.32b. from $1.25b. It also declared a quarterly dividend of 30 agorot per American Depositary Receipt. Analyst expectations for EPS ranged from 36 cents to 43 cents and for revenue of $1.24b. to $1.42b., as compiled by Thomson Financial Networks. Shares slipped 0.4% to NIS 179.50 on the Tel Aviv Stock Exchange but were up 2.4% at $39.27 in midday trading on Nasdaq. Analysts generally welcomed the results. "Teva returned to tradition and slayed the EPS consensus [of 38 cents] by two cents a share," enthused Clal Finance Batucha analyst Yisca Erez. William Blair & Co. called the results solid and IBI said, "There are many 'nice parts' to Teva's results... What's important is the strong cash flow of $385m., which will lighten the purchase of Ivax." Teva, which is one of the world's largest manufacturers of generic drugs, agreed in July to buy its Florida-based rival for $7.4b. and expects the transaction to close late this year or early in 2006. Ivax said, on Tuesday, that third-quarter net profit jumped 25% to $55.4m., EPS rose to 20 cents from 17 cents, and revenue climbed 41% to $617.7m. Global sales of Teva's multiple sclerosis treatment Copaxone jumped 27% to $307m., with the drug leading the market in total and new prescriptions, Teva said citing a survey from consulting company IMS. In addition, overall European pharmaceutical sales rose 24% to $342m., primarily due to increased sales of Copaxone and to sales of products that were not sold in the comparable quarter. Teva also has a big pipeline, with 145 product applications awaiting final approval by the US Food and Drug Administration. However, not everything in the earnings report was rosy. Operating profit slipped 1.7% as selling, general and administrative expenses rose 18%, primarily because of a profit-sharing agreement with Barr for hay fever and allergy drug Fexofenadine. Furthermore, North American pharmaceutical sales slipped 1.5% to $708m. due to lower sales of generic drugs in the US. Nine-month net profit rose to $767.4m. from $53m., diluted EPS rose to $1.14 from 8 cents and sales rose to $3.85b. from $3.48b.

Join Jerusalem Post Premium Plus now for just $5 and upgrade your experience with an ads-free website and exclusive content. Click here>>

Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection